Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 309-317

  Usall, Judith ^a,b,c   Huerta Ramos, Elena ^a,b,c   Labad, Javier ^c,d,e   Cobo, Jesús ^c,d   Núñez, Christian ^a   Creus, Marta ^e   Parés, Gemma García ^c,d,f   Cuadras, Daniel ^a   Franco, José ^b,e   Miquel, Eva ^a   Reyes, Julio César ^b,e   Roca, Mercedes ^a  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c Catalan Group in Women's Mental Health Research (GTRDSM)   (Spain)

^d Centre de Salut Mental   (Spain)

^e Reus   (Spain)

^f Cap EAE Salut Mental   (Andorra)

Author keywords

SERM negative symptoms estrogen

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RALOXIFENE; NEUROLEPTIC AGENT; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GROUP DYNAMICS; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; SEXUAL DYSFUNCTION; SIMPSON-ANGUS SCALE; SWEAT GLAND DISEASE; THROMBOPHLEBITIS; TIME; TIME INTERACTION; TREATMENT RESPONSE; UKU SIDE EFFECT RATING SCALE; UTERUS DISEASE; VAGINA BLEEDING; WEIGHT GAIN; AGED; COMBINATION DRUG THERAPY; MIDDLE AGED; OUTCOME ASSESSMENT;

AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; POSTMENOPAUSE; RALOXIFENE HYDROCHLORIDE; SCHIZOPHRENIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84964847596     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv149     Document Type: Article

References (43)

1. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand. 2000;401:3-38.
2. Usall J, Haro JM, Ochoa S, Márquez M, Araya S; Needs of Patients with Schizophrenia group. Influence of gender on social outcome in schizophrenia. Acta Psychiatr Scand. 2002;106:337-342.
3. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198.
4. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16:185-194.
5. Di Paolo, T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci. 1994;5:27-41.
6. Riecher-Rössler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci. 2011;8:155-171.
7. Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen, A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology. 2001;26:27-35.
8. Meesters PD, de Haan, L, Comijs HC, et al. Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a Dutch catchment area. Am J Geriatr Psychiatry. 2012;20:18-28.
9. Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: A double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1007-1012.
10. Kulkarni J, de Castella, AR, Fitzgerald PB, et al. Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry. 2008;65:955-960.
11. Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment- resistant schizophrenia: A large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015;20:695-702.
12. Chua WL, de Izquierdo, SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst Rev. 2005;19:CD004719.
13. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360:573-587.
14. MacGregor J, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151-196.
15. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10:905-912.
16. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: Tissue actions and potential for CNS protection. CNS Drug Rev. 2002;8:309-330.
17. Barreto G, Santos-Galindo M, Diz-Chaves Y, et al. Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. Endocrinology. 2009;150:5010-5015.
18. Cerciat M, Unkila M, Garcia-Segura LM, Arevalo MA. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein- 10 by astrocytes exposed to inflammatory challenge in vitro. Glia. 2010;58:93-102.
19. Landry M, Lévesque D, Di Paolo, T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology. 2002;76:214-222.
20. Bourque M, Morissette M, Di Paolo, T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1, 2, 3, 6- Tetrahydropyridine mice. Neurobiol Aging. 2014;35:2347-2356.
21. Wong J, Seeman MV, Shapiro H. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatr Psychiatry. 2003;11:697-698.
22. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72:1552-1557.
23. Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010;35:1142-1147.
24. Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: A randomized double-blind and placebo controlled trial. Daru. 2014;22:55.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
27. Bieber E, Sanfilippo J, Horowitz I. Clinical Gynecology. Philadelphia, PA: Churchill Livingstone; 2006.
28. Declaration of Helsinki World Medical Association. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Bulletin of the World Health Organization. 2001; 79:373-374.
29. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989;7:49-58.
30. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
31. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic- Treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
32. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645-692.
33. Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20:685-694.
34. Kindler J, Weickert CS, Skilleter AJ, Catts SV, Lenroot R, Weickert TW. Selective estrogen receptor modulation increases hippocampal activity during probabilistic association learning in schizophrenia. Neuropsychopharmacology. 2015;40:2388-2397.
35. Rodante DE, Usall J. Raloxifene as adjuvant in the treatment of schizophrenia: A review of efficacy and safety issues. J of Symptoms and Signs. 2014;3:229-237.
36. Maricic M, Gluck O. Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother. 2002;3:767-775.
37. Iikuni N, Hamaya E, Nihojima S, et al. Safety and effectiveness profile of raloxifene in long- Term, prospective, postmarketing surveillance. J Bone Miner Metab. 2012;30:674-682.
38. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: A PET study. Biol Psychiatry. 2000;48:854-860.
39. DonCarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology. 2009;34: S113-S122.
40. Velázquez-Zamora DA, Garcia-Segura LM, González- Burgos I. Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats. Horm Behav. 2012;61:512-517.
41. Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013;68:467-481.
42. Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93:136-143.
43. Kirkpatrick B, Fenton WS, Marder SR. The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.